Investigate the effects of milk fat with or without milk fat globule membranes (MFGM) on blood lipid profile, vascular function, insulin sensitivity, inflammation and gene expression. Overweight subjects will be randomized to one of 2 groups with different types of dairy products: 1)butter oil; 2) cream (milk fat with MFGM).
Dairy foods are a major component of the nordic diet. Epidemiological data suggest potential health effects of dairy foods with regard to obesity related disorders. Low-fat dairy foods have shown to be protective, but also high-fat products have been linked to reduced risk in some studies. It is well known that dairy products increase LDL-cholesterol in blood, but effects on glucose metabolism are unclear. Intervention trials are needed to clarify the health effects of dairy foods. Some data have indicated that cheese and milk may have less hypercholesterolemic effect compared with butter. Our hypothesis is that milk fat globule membranes (MFGM), present in all dairy products except butter, can affect blood lipid profile, vascular function, insulin sensitivity, inflammation and gene expression. Such idea might explain why different dairy products could have different effects on cholesterol levels. The investigators aim to conduct a controlled study to investigate this. Overweight subjects will be randomized to one of 2 groups with different types of dairy products: 1)butter oil; 2) cream (milk fat with MFGM).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
52
Daily intake of 40 g butter oil
Daily intake of 100 g cream (40%)
Uppsala university, Dept of public health and caring sciences; Clinical nutrition and metabolism
Uppsala, Sweden
LDL-cholesterol
Time frame: 8 weeks
Other major blood lipids
HDL-cholesterol, total cholesterol, triglycerides, apolipoproteins
Time frame: 8 weeks
Homeostasis model of assessment - insulin resistance
Insulin and glucose
Time frame: 8 weeks
Peripheral blood mononuclear cell gene expression
Time frame: 8 weeks
Inflammatory markers
C-reactive protein, Tumor necrosis factor alfa receptor 2, Interleukin-1-receptor antagonist
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.